Business Description
ENvue Medical Inc
NAICS : 334510
SIC : 3842
ISIN : US63008J8844
Total Employee Number:
14Description
ENvue Medical Inc is a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings. It focuses on two technology platforms: the ENvue Navigation Platform, which provides an electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract; FDA 510(k) cleared for adult use, it provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure. Its Medical advances non-invasive therapy and minimally invasive navigation, with a commitment to patient safety, clinical usability, and technology innovation in healthcare environments, and the company's acoustic-based therapeutic technologies.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.85 | |||||
Equity-to-Asset | 0.8 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.1 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -5.27 | |||||
Beneish M-Score | -6.74 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -58.8 | |||||
3-Year EBITDA Growth Rate | 64.6 | |||||
3-Year EPS without NRI Growth Rate | 72 | |||||
3-Year FCF Growth Rate | 69.7 | |||||
3-Year Book Growth Rate | -47.9 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 56.46 | |||||
9-Day RSI | 55.09 | |||||
14-Day RSI | 49.07 | |||||
3-1 Month Momentum % | -58.82 | |||||
6-1 Month Momentum % | -85.56 | |||||
12-1 Month Momentum % | -93.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.9 | |||||
Quick Ratio | 0.57 | |||||
Cash Ratio | 0.33 | |||||
Days Inventory | 329.6 | |||||
Days Sales Outstanding | 45.05 | |||||
Days Payable | 69.55 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -318.6 | |||||
Shareholder Yield % | -119.26 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -12.43 | |||||
Operating Margin % | -623.29 | |||||
Net Margin % | -923.2 | |||||
EBITDA Margin % | -577.17 | |||||
FCF Margin % | -569.14 | |||||
OCF Margin % | -565.84 | |||||
ROE % | -54.68 | |||||
ROA % | -43.59 | |||||
ROIC % | -30.93 | |||||
3-Year ROIIC % | -17.89 | |||||
ROC (Joel Greenblatt) % | -5210.97 | |||||
ROCE % | -35.81 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.04 | |||||
PB Ratio | 0.05 | |||||
EV-to-EBIT | -0.22 | |||||
EV-to-EBITDA | -0.24 | |||||
EV-to-Revenue | 1.36 | |||||
EV-to-Forward-Revenue | 8.11 | |||||
EV-to-FCF | -0.24 | |||||
Price-to-GF-Value | 0.09 | |||||
Earnings Yield (Greenblatt) % | -454.55 | |||||
FCF Yield % | -311.49 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:FEED
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ENvue Medical Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2.181 | ||
| EPS (TTM) ($) | -30.47 | ||
| Beta | 1.2432 | ||
| 3-Year Sharpe Ratio | -2.03 | ||
| 3-Year Sortino Ratio | -1.93 | ||
| Volatility % | 95.18 | ||
| 14-Day RSI | 49.07 | ||
| 14-Day ATR ($) | 0.054919 | ||
| 20-Day SMA ($) | 0.381625 | ||
| 12-1 Month Momentum % | -93.45 | ||
| 52-Week Range ($) | 0.29 - 17.4 | ||
| Shares Outstanding (Mil) | 9.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ENvue Medical Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ENvue Medical Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-04 10:00 | In 108 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 86 days | ||
| Second quarter earnings results for 2026 | 2026-08-17 | 0.44 (+19.07%) | ||
| First quarter earnings results for 2026 | 2026-05-18 | 1.10 (-3.95%) | ||
| Annual report for 2025 | 2026-04-15 | 1.57 (-3.68%) | ||
| General meeting for 2025 | 2025-12-04 10:00 | 4.10 (+3.54%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 4.69 (-0.21%) | ||
| Second quarter earnings results for 2025 | 2025-08-19 | 6.35 (+5.31%) | ||
| 0.1:1 Stock Split | 2025-08-12 | 7.72 (-0.68%) | ||
| First quarter earnings results for 2025 | 2025-05-20 | 13.00 (-0.76%) |
Show
Entries
ENvue Medical Inc Frequently Asked Questions
What is ENvue Medical Inc(FEED)'s stock price today?
The current price of FEED is $0.43. The 52 week high of FEED is $17.40 and 52 week low is $0.29.
When is next earnings date of ENvue Medical Inc(FEED)?
The next earnings date of ENvue Medical Inc(FEED) is 2026-11-13 Est..
Does ENvue Medical Inc(FEED) pay dividends? If so, how much?
ENvue Medical Inc(FEED) does not pay dividend.
Guru Commentaries on NAS:FEED
No articles.
Press Release
Articles on ENvue Medical Inc
Headlines
See More- 1
Aug 12, 2026
ENvue Medical secures up to $50M equity facility to fund growth plans
Seeking Alpha • 8:05am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers